Lorbrena

Active Ingredient(s): Lorlatinib
FDA Approved: * November 2, 2018
Pharm Company: * PFIZER INC
Category: Cancer

Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.[1] Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 7.1 Clinical studies 7.2 Approval... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lorbrena 25 mg Oral Tablet, Film Coated
NDC: 0069-0227
Labeler:
Pfizer Laboratories Div Pfizer Inc
Lorbrena 100 mg Oral Tablet, Film Coated
NDC: 0069-0231
Labeler:
Pfizer Laboratories Div Pfizer Inc